Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy

Purpose: to illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to epidermal growth factorreceptor + non-small cell lung cancer (egfr+ nsclc). case report: a 63-year-old asian male presented to ophthalmology with a complaint of left blurry vision. initial ophthalmic exam revealed a choroidal lesion and imaging results highlighted a spiculated lung mass with brain and bony metastases. osimertinib was chosen for its specificity and ability to cross the blood–brain barrier. follow-up ophthalmic and radiographic imaging were repeated over the course of treatment. conclusion: after the initiation of osimertinib, ophthalmic and computed tomography imaging highlighted the regression of the ocular metastatic disease and primary malignancy, respectively. osimertinib is an effective first-line treatment of egfr+ nsclc and corresponding metastatic sites. additionally, ophthalmic imaging can be used to monitor general response to chemotherapy agents when ocular metastasis is identified.